News

Lynparza, which is used to treat types of breast, ovarian, prostate, and pancreatic cancer, can cause side effects. Learn about its more common side effects.
Lynparza (olaparib) is a prescription drug used to help treat certain kinds of cancer. Lynparza’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...
Lynparza is used to treat certain types of cancer. Find out what the recommended dosage is, how to take the drug, and more. Lynparza is used to treat certain types of cancer.
Lynparza (olaparib) is a brand-name tablet that’s prescribed for certain types of cancer. The cost of the drug with and without insurance can depend on several factors, such as whether Lynparza ...
RAHWAY, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in ...
AstraZeneca and Merck's LYNPARZA Reduced the Risk of Disease Progression or Death by 42 Percent Versus Chemotherapy in Phase 3 OlympiAD TrialFirst PARP Inhibitor Approved in the EU for This ...
Lynparza received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the treatment of germline BRCA-mutated HER2-negative ...
In a study published last week in The New England Journal of Medicine, British drugmaker AstraZeneca said that in a late-stage trial, its drug Lynparza reduced the risk of relapse and death in ...
So far, the studies demonstrate that Lynparza has activity in cancer patients with and without inherited BRCA mutations. When combined with DNA-damaging chemotherapy or new targeted drugs, PARP ...
AstraZeneca’s Lynparza has become the first drug in its class approved to treat breast cancer, after the FDA allowed it an expanded licence. The FDA approved Lynparza (olaparib) as a treatment ...
The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York (Reuters) - AstraZeneca said on Wednesday its cancer drug, Lynparza, was ...
AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments.